Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia

Haemophilia

Volumn 12, Issue 5, 2006, Pages 514-517

  Rattray, B ^a   Nugent, D J ^a   Young, Guy ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Arthropathy; COX 2 inhibitors; Haemophilia; Therapy

Indexed keywords

CELECOXIB; ROFECOXIB;

ADOLESCENT; ADULT; ANALGESIA; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERTENSION; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; SCHOOL CHILD; SYNOVITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; CHILD; CHRONIC DISEASE; CYCLOOXYGENASE 2 INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MIDDLE AGED; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; SYNOVITIS; TREATMENT OUTCOME;

EID: 33747194104     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01311.x     Document Type: Article

References (12)

1. Dunn AL. Management and prevention of recurrent hemarthrosis in patients with hemophilia. Curr Opin Hematol 2005; 12: 390-4.
2. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: Overexpression of mdm2 oncogene. Blood 2004; 104: 2060-4.
3. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
4. Bragodottir G, Onundarson PT. Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. Haemophilia 2002; 8: 828-33.
5. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005; 11: 240-4.
6. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003; 74: 282-90.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
8. Ruschitzka FT. The APPROVe Study: What we should learn from the VIOXX withdrawal. Curr Hypertens Rep 2005; 7: 41-3.
9. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have differential odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64.
10. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
11. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-4.
12. Kulkarni R, Soucie J, Evatt B. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematology 2005; 79: 36-42.